U.S. state attorneys general sue Purdue Pharma over opioid epidemic




  • In US
  • 2018-05-15 20:21:14Z
  • By By Tina Bellon
FILE PHOTO: Bottles of prescription painkiller OxyContin made by Purdue Pharma LP sit on a shelf at a local pharmacy in Provo
FILE PHOTO: Bottles of prescription painkiller OxyContin made by Purdue Pharma LP sit on a shelf at a local pharmacy in Provo  

By Tina Bellon

NEW YORK (Reuters) - Six more U.S. states on Tuesday announced lawsuits against OxyContin maker Purdue Pharma LP, accusing the company of fueling a national opioid epidemic by deceptively marketing its prescription painkillers to generate billions of dollars in sales.

U.S. state attorneys general of Nevada, Texas, Florida, North Carolina, North Dakota and Tennessee also said Purdue Pharma violated state consumer protection laws by falsely denying or downplaying the addiction risk while overstating the benefits of opioids.

"It's time the defendants pay for the pain and the destruction they've caused," Florida State Attorney General Pam Bondi told a press conference.

Florida also sued drugmakers Endo Pharmaceuticals Inc, Allergan, units of Johnson & Johnson and Teva Pharmaceutical Industries and Mallinckrodt, as well as drug distributors AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp.

The companies did not immediately respond to requests for comment on the lawsuit.

Teva issued a statement in which it emphasized the importance of safely using opioids.

The Healthcare Distribution Alliance, an umbrella group for drug distributors, said in a statement that accusations that distributors were responsible for the abuse of opioid prescriptions defied common sense and lacked understanding of how the pharmaceutical supply chain worked.

"Those bringing lawsuits would be better served addressing the root causes, rather than trying to redirect blame through litigation," John Parker, the organization's senior vice president, said in a statement.

Lawsuits have already been filed by 16 other U.S. states, Puerto Rico against the privately held company. Purdue in February announced a halt to its promotion of opioids to physicians after widespread criticism of the ways drugmakers market addictive painkillers.

Purdue, based in Stamford, Connecticut, issued a statement in which it denied the accusations and that its drugs were approved by the U.S. Food and Drug Administration and accounted for only 2 percent of all opioid prescriptions.

"We are disappointed that after months of good faith negotiations working toward a meaningful resolution to help these states address the opioid crisis, this group of attorneys general have unilaterally decided to pursue a costly and protracted litigation process," Purdue said.

Opioids were involved in more than 42,000 overdose deaths in 2016, the last year for which data was available, according to the U.S. Centers for Disease Control and Prevention.

Separate litigation involving at least 433 lawsuits by U.S. cities and counties has been consolidated in a federal court in Cleveland, Ohio. The defendants include opioid manufacturers Purdue Pharma LP, J&J, Teva, Endo International Plc and drug distributors AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp.

The action accused the drugmakers of deceptively marketing opioids and drug distributors of ignoring indications that the painkillers were being diverted for improper uses.

The federal judge overseeing the consolidated litigation, U.S. District Judge Dan Polster, has been pushing for a global settlement and has invited state attorneys general with state court cases not before him to participate in those talks.

Despite filing separate lawsuits, the six attorneys general on Tuesday said they would continue to engage in settlement discussions with Purdue and other companies.

"You always want to settle and prevent a prolonged litigation, but we're sending a message that we're fully prepared to go to war," Florida's Bondi said.


(Reporting by Tina Bellon Editing by Bernadette Baum and Bill Berkrot)

COMMENTS

More Related News

US property crisis looms as sea level rises, experts warn

 
US property crisis looms as sea level rises, experts warn  

Along sun-splashed shorelines in the US state of Florida, home prices are on the rise, developers are busy building new complexes, and listings just blocks from the beach describe homes that are "not in a flood zone," meaning no flood insurance is required. A reality check may come sooner than many may think, according to a report out Monday by the Union of Concerned Scientists, which finds as many as 64,000 coastal residences worth $26 billion in Florida are at risk of chronic flooding in the next 30 years, the life of a typical mortgage. Across the United States, 311,000 coastal homes with a collective market value of about $120 billion in today's dollars are at risk of chronic...

Property crisis looms due to sea level rise, experts warn

 
Property crisis looms due to sea level rise, experts warn  

Along Florida's sun-splashed shorelines, home prices are on the rise, developers are busy building new complexes, and listings just blocks from the beach describe homes that are "not in a flood zone," meaning no flood insurance is required. A reality check may come sooner than many may think, according to a report out Monday by the Union of Concerned Scientists, which finds as many as 64,000 coastal residences worth $26 billion in Florida are at risk of chronic flooding in the next 30 years, the life of a typical mortgage. Across the United States, 311,000 coastal homes with a collective market value of about $120 billion in today's dollars are at risk of chronic flooding by 2045, it said.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US

facebook
Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.